EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab

Chad A Reade
Apar Kishor Ganti

1Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA; 2Section of Oncology-Hematology, Department of Internal Medicine, VA Medical Center, Omaha, NE, USA

Abstract: Chemotherapy alone has limited ability to significantly improve survival in non-small lung cancer (NSCLC) beyond what has already been achieved. The epidermal growth factor (EGF) pathway plays a vital role in the pathogenesis and progression of NSCLC. Two classes of drugs inhibit the EGF receptor (EGFR) pathway: small molecules that inhibit the intracellular tyrosine kinase activity of the receptor, and monoclonal antibodies that target the extracellular domain in the ligand-binding region. Cetuximab is a human–mouse chimeric immunoglobulin G1 class monoclonal antibody directed against EGFR. Preclinical studies with cetuximab suggested that there was inhibition of growth of human NSCLC cell lines. Cetuximab is currently the focus of intense investigation in various patient populations with NSCLC. This review focuses on clinical trials of cetuximab in NSCLC and identifies future directions with this agent.

Keywords: non-small cell lung cancer, EGFR, cetuximab, monoclonal antibodies

Introduction

Lung cancer is the most common cause of cancer death in both men and women in the United States and around the world.1,2 Approximately 85% of lung cancers are non-small cell lung cancers (NSCLC), and approximately 75% of these are metastatic at diagnosis.3,4 While therapy has evolved over the last few decades and has repeatedly been shown to improve survival, the five-year overall survival of patients with NSCLC is a dismal 15%.2 The significant toxicity associated with cytotoxic chemotherapy also excludes a number of patients based on age, co-morbidities, or poor performance status.5

Platinum-based doublets have been established therapy for metastatic NSCLC since the mid-1990s.6 Numerous studies have shown that, among cytotoxic chemotherapeutics, two-agent therapy is more effective than single-agent therapy.7–9 Using three or more cytotoxic therapies does not improve efficacy and increases toxicity.10,11 Commonly used chemotherapy doublets incorporate cisplatin or carboplatin with agents that include paclitaxel, docetaxel, vinorelbine, gemcitabine, or more recently pemetrexed. Many regimens given in the first-line setting result in a median survival time of eight to 10 months, with one- and two-year survival rates of 35% to 45%, and 10% to 20%, respectively.12

While studies with new chemotherapeutic agents are ongoing, evidence now available suggests that chemotherapy alone has limited ability to significantly improve survival beyond what has already been achieved.13 Furthermore, toxicities
associated with these medicines not only exclude some patients based on poor performance status but also preclude a number of patients from completing chemotherapy courses as scheduled at the full therapeutic dose. As the knowledge of tumor biology has improved, biologic agents that specifically target molecules thought to be critical to tumorigenesis have emerged. Theoretically, the greater specificity against malignant cells with targeted agents should result in simultaneously greater efficacy and less toxicity, thereby allowing usage in patients previously excluded from consideration of systemic therapy.

Biologic therapies targeting the vascular endothelial growth factor receptor (VEGFR) and the endothelial growth factor receptor (EGFR) are undergoing evaluation to determine their potential role in NSCLC. Bevacizumab, a monoclonal antibody against VEGFR, and erlotinib, a small molecule inhibitor of the intracellular tyrosine kinase of EGFR, currently are indicated for use in NSCLC. Cetuximab, a monoclonal antibody against EGFR, is currently being studied extensively. Here we review the role of cetuximab in the treatment of NSCLC.

**EGFR in lung cancer**

EGFR, whose ligands include epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), is a member of the ErbB1 (HER-1) family of receptors. Binding of the extracellular domain by EGF or TGF-α induces dimerization of EGFR, leading directly to activation of kinase activity in the intracellular domain. Receptor tyrosine kinases transfer phosphate groups from bound ATP to tyrosine residues on the carboxy (C) terminal portion of the receptor. Multiple intracellular cascades are activated when adaptor molecules recognize phosphotyrosines on the C-terminal of EGFR: 1. KRAS/RAF/MEK/MAP kinase pathway via binding of Grb2/SOS; 2. PI3-K pathway and the 3. STAT3/5 pathway (Figure 1). The complexity (ie, pathway overlap and crosstalk) of intracellular signaling via tyrosine kinases is vastly oversimplified by a cursory discussion, but it is evident that activation

![Figure 1 EGFR signaling pathway. The figure depicts the downstream pathways following activation of the EGF receptor: Binding of a ligand to the receptor activates the tyrosine kinase (K) which then activates the downstream signaling pathways that eventually lead to increased proliferation, cell cycle progression and decreased apoptosis. Solid arrows indicate stimulation, while dashed arrows indicate suppression. Sites of action of the tyrosine kinase inhibitors (TKIs) and monoclonal antibodies are also shown. Abbreviations: EGF, endothelial growth factor receptor; PI3K, phosphoinositide-3-kinase; STAT, signal transducer and activator of transcription; JAK, Janus kinase; pAKT, phospho AKT; MAPK, mitogen-activated protein kinase.](image-url)
of these pathways serves to increase transcription and cellular proliferation, and inhibit apoptosis.\(^20\) In malignant cells, they also contribute to angiogenesis and metastasis.\(^21,22\)

The EGF pathway plays a vital role in the pathogenesis and progression of NSCLC. Approximately 50%–80% of NSCLC demonstrate overexpression of EGFR activity.\(^23–27\) Although the majority of NSCLC overexpress EGFR at diagnosis, expression appears to vary with histology (65% in adenocarcinomas to 84% in squamous carcinomas).\(^28\) EGFR expression also seems to correlate with stage at presentation. EGFR levels are higher in pathological stage IV NSCLC than in stage I and II disease and higher in cases with mediastinal involvement than in cases without it.\(^29\)

Although EGFR expression is important in the development and progression of malignancy, its prognostic significance is unclear. Some studies observed a correlation between EGFR expression and tumor invasiveness,\(^30\) and poorer survival,\(^31–33\) while there was no relation seen in another study.\(^34\) EGFR amplification in a subset of patients from the INTACT trials\(^34,35\) appeared to correlate with a response to gefitinib (Iressa\(^®\); AstraZeneca, Wilmington, DE); but no effect on overall survival was seen.\(^36\) In a meta-analysis of 2792 patients enrolled in 18 different studies, Nakamura and colleagues found that EGFR overexpression had no impact on survival in patients with NSCLC (hazard ratio [HR], 1.14; 95% confidence interval [CI]: 0.97–1.34; \(p = 0.1\)).\(^37\) Other studies however found that not only is EGFR expression increased in NSCLC, but its presence is associated with poor prognosis.\(^30–32,38\)

Various mechanisms for upregulation of receptor activity in NSCLC have been discovered:

- Increased production of EGFR with or without increased EGFR gene copy number.\(^39\)
- EGFR mutations resulting in constitutive activation of the receptor, regardless of ligand binding.\(^39,40\)
- Increased production of ligands, TGF-\(\alpha\), or EGF or related proteins.\(^24\)

The most common clinically relevant assays for EGFR expression in NSCLC include assays for gene amplification,\(^41\) immunohistochemical (IHC) stains for protein overexpression,\(^42\) and detection of specific mutations by DNA sequencing.\(^43\) EGFR copy number can be measured using fluorescence in situ hybridization (FISH),\(^44\) while EGFR mutations can be detected using sequencing analyses of DNA.\(^45\)

**Targeted agents against EGFR**

Two classes of drugs inhibiting the EGFR pathway are currently in clinical usage: small molecules that inhibit the intracellular tyrosine kinase activity of the receptor, and monoclonal antibodies that target the extracellular domain in the ligand-binding region. Gefitinib (Iressa\(^®\); AstraZeneca) and Erlotinib (Tarceva\(^®\); OSI Pharmaceuticals, Inc. Melville, NY) are the two most studied drugs in the EGFR-tyrosine kinase inhibitor class. Canertinib (C11033), lapatinib (GW572016, Tykerb\(^®\); GlaxoSmithKline Research Triangle Park, NC), PKI116, and EKB569 are examples of other drugs in this class currently in development. The most well-known EGFR monoclonal antibody is cetuximab (Erbitux\(^®\); Bristol-Myers Squibb Company, Princeton, NJ). Panitumumab (AMG706, Vectibix\(^®\); Amgen Inc., Thousand Oaks, CA), matuzumab (EMD7000), and nimotuzumab (h-R3) are EGFR monoclonal antibodies currently being developed.

**Clinical trials of tyrosine kinase inhibitors**

**Gefitinib**

Gefitinib was the first EGFR-TKI tested in clinical trials. Two phase II trials (IDEAL-1 and IDEAL-2) showed that gefitinib produced a response rate of 9%–18% and overall disease control rate of 43%–50% in patients with relapsed NSCLC.\(^46,47\) However the phase III ISEL trial that randomized nearly 1700 patients with advanced NSCLC to gefitinib or placebo, failed to reveal an overall survival benefit.\(^48\) A recent phase III trial (INTEREST) showed that gefitinib was noninferior to docetaxel in terms of overall survival (OS) in patients with relapsed NSCLC; it was also better tolerated and correlated with better quality of life.\(^49\) Similarly, another randomized phase II study comparing gefitinib with vinorelbine in chemo-naïve elderly patients with advanced non-small-cell lung cancer found that gefitinib had similar response rates and progression-free (PFS) and overall survival to vinorelbine.\(^50\)

Two trials (INTACT-1 and INTACT-2) that combined gefitinib with chemotherapy in the first-line setting,\(^34,35\) did not show any survival benefit from the addition of gefitinib. On the other hand, although the IPASS (Iressa Pan-Asia Study) comparing gefitinib with carboplatin/paclitaxel for previously untreated Asian never- or light-smokers with advanced adenocarcinoma found no difference in overall survival,\(^31\) patients who had EGFR gene mutations had a greater response rate (71.2% vs 41.3%) and improved overall survival (HR, 0.48; 95% CI: 0.36–0.64; \(p < 0.0001\)) with gefitinib.

**Erlotinib**

Unlike gefitinib, erlotinib has shown clinical efficacy that has resulted in its unrestricted US Food and Drug Administration
(FDA) approval in NSCLC. BR21, a randomized phase III trial of 731 patients with stage IIIB or IV NSCLC showed that patients randomized to erlotinib had a statistically significant increase in overall survival, PFS, and overall response rate.15 However, similar to the results seen with gefitinib, phase III trials evaluating the combination of a platinum-based doublet alone or with erlotinib, gemcitabine – cisplatin (TALENT)52 and carboplatin – paclitaxel (TRIBUTE)53 did not show any advantage to the addition of erlotinib.

Cetuximab

Introduction

Cetuximab is a human-mouse chimeric immunoglobulin G1 (IgG1) class monoclonal antibody directed against the EGFR with proven second- or third-line efficacy in colorectal54 and head and neck cancers.55,56 This monoclonal antibody binds to the extracellular ligand-binding domain with affinity five times greater than natural ligands like TGF-α and EGF.57 Binding of cetuximab prevents dimerization and subsequent activation by auto-phosphorylation of the receptor in the intracellular kinase domain.58 The receptor-antibody complex is internalized and degraded, thereby decreasing EGFR availability.59 In vitro studies show the antibody also mediates antibody-dependent cellular cytotoxicity (ADCC) against the receptor.60 Preclinical studies with cetuximab suggested that there was inhibition of growth of human NSCLC cell lines and other EGFR-expressing cell lines in vitro61–63 and in athymic nude mice,61,63 and combinations with cytotoxic agents produced synergistic greater delay of tumor growth.63,64 In addition, cetuximab had a potentiating effect on the growth delay produced by radiotherapy.65

Doody and colleagues studied the activity of cetuximab with NSCLC lines bearing both wild-type EGFR and those with activating mutations in the intracellular kinase domain: not only those known to confer sensitivity to gefitinib and erlotinib (L858R and delL747-T753insS) but also the TKI-resistant mutation T790M.66 They found that ligand-independent phosphorylation of the T790M lines was unaffected by cetuximab (as measured by assays for phosphorylated EGFR, and downstream phosphorylated molecules Akt and MAPK) and cellular proliferation was inhibited. Previous studies had shown that binding of EGFR antibodies to wild-type EGFR resulted in increased internalization and degradation of the receptor-antibody complex without stimulating phosphorylation of the receptor.67 Similarly, Doody and colleagues demonstrated that mutant EGFR (including T790M) was internalized and degraded at a higher rate than wild-type EGFR.66

Clinical trials

Given the promising results of these preclinical experiments, cetuximab was introduced into clinical trials. While cetuximab was generally well tolerated, the common side effects seen in phase I testing included: skin toxicity, nausea, fever/chills, asthenia, and elevation of transaminases; grade 3 or 4 toxicities included dyspnea, aseptic meningitis, anaphylactic reaction, diarrhea, and epiglottitis.68

First-line therapy

A phase I/II trial combining cetuximab with paclitaxel/carboplatin produced 65% overall disease control rate (partial response [PR], 26%; stable disease, 39%).69 Median PFS, OS, and one-year survival were 5 months, 11 months, and 40%, respectively. Similar results were seen when cetuximab was combined with gemcitabine and carboplatin (PR 28%; stable disease, 60%; median PFS, 5.3 months; median OS, 10.3 months; one-year survival, 45%).70 A randomized phase II study comparing vinorelbine/carboplatin with the same chemotherapy plus cetuximab71 suggested that addition of cetuximab led to better outcomes (odds ratio [OR], 35% vs 28%; median PFS, 5.0 vs 4.6 months; median OS, 8.3 vs 7.3). Similar results were seen in another randomized phase II study of gemcitabine plus cisplatin or carboplatin with or without cetuximab. Although the study design was non-comparative, addition of cetuximab seemed to improve outcomes in terms of PR (27.7% vs 18.2%), median PFS (5.1 vs 4.2 months), and median OS (11.99 vs 9.26 months).72

The results of these trials led to the conduct of the phase III FLEX trial,73 which randomized 1125 patients with EGFR overexpressing advanced NSCLC to cisplatin/vinorelbine with or without cetuximab. The basis for patient selection in this trial was presence of the EGFR staining by IHC, which the investigators defined as the presence of at least one EGFR-positive cell. This is the first study that has used IHC to determine eligibility for EGFR-targeted therapy.

Addition of cetuximab led to a significant improvement in overall survival (11.3 vs 10.1 months; HR, 0.871; P = 0.0441). One-year survival also was higher in the cetuximab group (47% vs 42%). Interestingly however there was no difference in PFS between the two groups. Though the benefit with the addition of cetuximab was modest, the results of this trial led to cetuximab being incorporated into the National Comprehensive Cancer Network (USA) guidelines for use in the first-line setting in combination with cisplatin.

Preliminary results of pre-specified subgroup analyses suggest a greater benefit with the addition of cetuximab in Caucasians. Caucasian patients who received cetuximab had a median survival of 10.5 months as opposed to 9.1 months in those who did not receive cetuximab (HR, 0.8; P = 0.0025). However although Asians had a better prognosis in general, there was no additional benefit to the addition of cetuximab. Median survival in the cetuximab group among Asians was 17.6 months as compared to 20.4 months in the placebo group (HR, 1.179; P = 0.4992).

Second-line therapy

Single agent cetuximab seems to result in outcomes similar to docetaxel, pemetrexed or erlotinib in patients with recurrent or progressive NSCLC, all of which are currently approved for the treatment of patients with NSCLC, who have failed first-line therapy. In this study by Hanna and colleagues, although the response rate was only 4.5% (3/66), 30.3% of patients had stable disease. Moreover, median time to progression and median OS were 2.3 and 8.9 months, respectively, and one-year survival was 43.9%, values numerically similar to those seen in studies with erlotinib, pemetrexed, and docetaxel. In the second-line setting, cetuximab was combined with docetaxel and demonstrated a response rate of 25% among 20 patients with minimal toxicities.

Combination with chemoradiotherapy

Positive results for the radio-sensitizing effects of cetuximab in head and neck cancer led investigators to test cetuximab in combination with synchronous radiotherapy following induction chemotherapy in chemotherapy-naïve stage III NSCLC patients. The toxicity results published thus far suggest that this is a safe regimen. The Cancer and Leukemia Group B (CALGB) conducted a randomized phase II study of thoracic radiation (70 Gy) along with carboplatin and pemetrexed for four cycles (arm A) or the same chemotherapy regimen along with cetuximab for additional six weeks (arm B). Subsequently all patients received four additional cycles of pemetrexed as consolidation therapy. The main adverse effects were hematologic with grades 3/4 neutropenia seen in 36% and 37% patients in arms A and B respectively and grades 3/4 thrombocytopenia in 30% and 34% of patients. Esophagitis (35% and 22%), fatigue (22% and 18%) and skin rash (3% and 22%) were the most common nonhematologic toxicities. These initial results suggest acceptable tolerability. Efficacy results of this study are awaited.

Currently, multiple studies are currently underway evaluating the role of cetuximab in different patient populations with NSCLC (Table 1). The results of these studies should help us understand the exact role of cetuximab in the treatment of NSCLC.

Targeting EGFR inhibitors

One of the major issues in the use of EGFR-targeted therapy in NSCLC has been the identification of patients who would actually benefit from these agents. Identifying predictive markers for a response to the EGFR-targeted therapy has been quite challenging. Most of the available information focuses on response to EGFR TKIs rather than cetuximab, since these agents have been in use for a longer period of time.

Clinical factors that can help predict response to EGFR TKIs have been investigated. A subset analysis of the BR21 trial showed that women, nonsmokers, patients with adenocarcinoma and patients with Asian ethnicity had better outcomes with erlotinib. A subset analysis of the IDEAL-1 trial revealed that patients with adenocarcinoma had superior outcomes, despite the observation that high EGFR expression is more common in squamous cell carcinomas than in adenocarcinomas. Mutation studies of the EGFR gene showed that somatic mutations in the tyrosine kinase domain of the EGFR gene predicted for response to gefitinib and were associated with an improved outcome.

Correlative studies from the ISEL trial showed that a high EGFR gene copy number was a predictor of clinical benefit from gefitinib. Patients whose tumors expressed the EGFR protein and who were treated with gefitinib had a slightly greater survival advantage (HR, 0.77; 95% CI: 0.56–1.08; P = 0.126). Also, patients with EGFR mutations had higher response rates than patients without EGFR mutations (37.5% vs 2.6%). In another analysis of 204 patients treated with gefitinib, Hirsch and colleagues found that although increased EGFR and HER2 gene copy number, EGFR protein overexpression, EGFR mutations, and pAKT overexpression were all associated with significantly higher response rates only increased EGFR gene copy number and EGFR protein overexpression correlated with improved survival.

In similar studies on samples from patients treated with erlotinib, there was no association between the presence of EGFR mutations and responsiveness to erlotinib. However similar to the findings of Hirsch and colleagues, in this analysis, expression of EGFR and an increased number of copies of EGFR were associated with responsiveness to erlotinib but not with increased survival.
<table>
<thead>
<tr>
<th>Name/ID</th>
<th>Population</th>
<th>Phase</th>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT00112294</td>
<td>Advanced or metastatic, chemotherapy naïve</td>
<td>III</td>
<td>Taxane + carboplatin ± cetuximab</td>
</tr>
<tr>
<td>NCT00097214</td>
<td>Stage III/BIV</td>
<td>II</td>
<td>Carboplatin + cetuximab</td>
</tr>
<tr>
<td>NCT00097272</td>
<td>Stage III/BIV</td>
<td>II</td>
<td>Carboplatin + paclitaxel + cetuximab</td>
</tr>
<tr>
<td>NCT00112346</td>
<td>Stage III/BIV</td>
<td>II</td>
<td>Gemcitabine + platinum ± cetuximab</td>
</tr>
<tr>
<td>NCT00118183</td>
<td>Stage III/BIV</td>
<td>II</td>
<td>Docetaxel + cetuximab or bortezomib</td>
</tr>
<tr>
<td>NCT00368992</td>
<td>Stage III/BIV</td>
<td>II</td>
<td>Cetuximab + paclitaxel + carboplatin + bevacizumab; maintenance cetuximab + bevacizumab</td>
</tr>
<tr>
<td>NCT00343291</td>
<td>Stage III/BIV or recurrent chemotherapy naïve</td>
<td>II</td>
<td>Cetuximab + paclitaxel + carboplatin + bevacizumab; maintenance cetuximab + bevacizumab</td>
</tr>
<tr>
<td>NCT00027755</td>
<td>Treatment naïve stage IV</td>
<td>lb/llla</td>
<td>Cetuximab + gemcitabine + carboplatin</td>
</tr>
<tr>
<td>NCT00193453</td>
<td>Unresectable stage III/IV</td>
<td>II</td>
<td>Cetuximab + gemcitabine + docetaxel</td>
</tr>
<tr>
<td>CALC-I</td>
<td>Advanced</td>
<td>II</td>
<td>Cetuximab + gemcitabine</td>
</tr>
<tr>
<td>NCT00251498</td>
<td>Advanced</td>
<td>II</td>
<td>Carboplatin + docetaxel + cetuximab</td>
</tr>
<tr>
<td>NCT00315185</td>
<td>Advanced</td>
<td>II</td>
<td>Cetuximab</td>
</tr>
<tr>
<td>NCT00408499</td>
<td>Advanced</td>
<td>II</td>
<td>Erlotinib + cetuximab</td>
</tr>
<tr>
<td>NCT00561054</td>
<td>Advanced</td>
<td>II</td>
<td>Cetuximab + cisplatin + gemcitabine</td>
</tr>
<tr>
<td>NCT00828841</td>
<td>Advanced</td>
<td>II</td>
<td>Cetuximab + either carboplatin + paclitaxel or platinum + gemcitabine/pemetrexed</td>
</tr>
<tr>
<td>NCT00842712</td>
<td>Advanced</td>
<td>II</td>
<td>Cilengitide + cetuximab + platinum-based chemotherapy</td>
</tr>
<tr>
<td>NCT00165334</td>
<td>Elderly, treatment naïve, advanced</td>
<td>II</td>
<td>Vinorelbine + cetuximab</td>
</tr>
<tr>
<td>NCT00673738</td>
<td>Locally advanced, poor PS, elderly</td>
<td>II</td>
<td>Cetuximab + conformal thoracic radiotherapy</td>
</tr>
<tr>
<td>NCT00820755</td>
<td>Maintenance</td>
<td>II</td>
<td>Cetuximab maintenance following platinum-based therapy</td>
</tr>
<tr>
<td>NCT00716456</td>
<td>Adenocarcinoma with acquired resistance to erlotinib</td>
<td>II</td>
<td>Erlotinib + cetuximab</td>
</tr>
<tr>
<td>NCT00694603</td>
<td>Progression on TKI</td>
<td>II</td>
<td>Cetuximab</td>
</tr>
<tr>
<td>NCT0063388</td>
<td>Recurrent</td>
<td>II</td>
<td>Cetuximab</td>
</tr>
<tr>
<td>NCT00103207</td>
<td>Recurrent</td>
<td>II</td>
<td>Cetuximab</td>
</tr>
<tr>
<td>NCT00162318</td>
<td>Recurrent</td>
<td>I</td>
<td>Gefitinib + cetuximab</td>
</tr>
<tr>
<td>NCT00216203</td>
<td>Recurrent</td>
<td>I/II</td>
<td>Pemetrexed + cetuximab</td>
</tr>
<tr>
<td>NCT00095199</td>
<td>Recurrent/progressive</td>
<td>III</td>
<td>Docetaxel vs cetuximab</td>
</tr>
<tr>
<td>NCT00118118</td>
<td>Recurrent/progressive</td>
<td>II</td>
<td>Cetuximab</td>
</tr>
<tr>
<td>NCT00203931</td>
<td>Recurrent/progressive</td>
<td>II</td>
<td>Cetuximab or cetuximab + pemetrexed</td>
</tr>
<tr>
<td>NCT00519831</td>
<td>Second-line</td>
<td>II</td>
<td>Vinflunine + cetuximab</td>
</tr>
<tr>
<td>NCT00115518</td>
<td>Stage III</td>
<td>II</td>
<td>Cetuximab + radiation</td>
</tr>
<tr>
<td>NCT00124618</td>
<td>Stage III</td>
<td>II</td>
<td>Cetuximab + radiation</td>
</tr>
<tr>
<td>NCT00288054</td>
<td>Stage III</td>
<td>I</td>
<td>Docetaxel + cetuximab + radiation</td>
</tr>
<tr>
<td>NCT00522886</td>
<td>Stage III</td>
<td>I</td>
<td>Carboplatin + gemcitabine followed by cetuximab + radiation + cisplatin + vinorelbine</td>
</tr>
<tr>
<td>NCT005333949</td>
<td>Stage III</td>
<td>II</td>
<td>Carboplatin + paclitaxel ± cetuximab + either standard or high-dose radiation</td>
</tr>
<tr>
<td>NCT00081302</td>
<td>Stage IIIA</td>
<td>II</td>
<td>Carboplatin + paclitaxel + cetuximab + radiation</td>
</tr>
<tr>
<td>NCT00492206</td>
<td>Stage IIIA/IIIIB</td>
<td>II</td>
<td>Cetuximab + radiation followed by consolidation chemotherapy</td>
</tr>
</tbody>
</table>
Three retrospective studies from Japan and Korea, where the somatic *EGFR* mutations are detected approximately thrice as common than in the United States and Europe have shown that response rates following treatment with gefitinib in patients with *EGFR* mutations ranged from 65%–83% as compared to 10%–15% for those without the mutations.\(^{84-86}\) This translated into an overall survival advantage for treatment with gefitinib in patients with the mutations.

Hirsch and colleagues analyzed tissue samples from patients enrolled onto a phase II trial of paclitaxel/carboplatin with either sequential (cetuximab weekly for one year following the completion of chemotherapy) or concurrent (weekly cetuximab during and for one year following chemotherapy) cetuximab therapy for *EGFR* status.\(^{87}\) Progression free survival and disease control rate (DCR) were statistically significantly better in FISH (+) patients, and there was a nonsignificant trend toward higher objective response rate (ORR) as compared to FISH (−) patients in both arms. The authors concluded that *EGFR* FISH status is a predictive factor for selection of NSCLC patients for cetuximab plus chemotherapy. Critics point out many potential flaws in attempting to draw conclusions based on these results and urge caution in interpreting them.\(^{88}\)

Although *EGFR*-targeted therapies have been approved for use without molecular testing, immunohistochemistry to detect *EGFR* protein overexpression, fluorescence in situ hybridization to detect *EGFR* gene amplification, and mutational analyses of the *EGFR* gene have all been proposed as candidates to help predict benefit from *EGFR*-directed therapy in NSCLC. In fact the FLEX trial was the first to incorporate the presence of *EGFR* positivity as an inclusion criterion for the study.\(^{73}\) However even in this trial, a rather loose definition of *EGFR* positivity was employed; patients who had even one cell staining for *EGFR* by IHC were considered *EGFR* positive.

As is evident from the disparity in the results from the studies discussed above, there is an urgent need for standardization of these assays. Without such standardization, routine utilization of these technologies to guide clinical decision making in a given patient will be difficult. In order to address this issue the Molecular Assays in NSCLC Working Group was convened under the sponsorship of Genentech Inc, Roche Pharmaceuticals, and OSI Pharmaceuticals, Inc, to evaluate the available molecular assays for use in the clinical trial setting and provide recommendations for application and interpretation of these tests.\(^{99}\) The recommendations from this group included the following:

- The minimum cell number to be evaluated should be: FISH: >100 assessable tumor cell nuclei, IHC/mutation: 2,000 cells, Direct sequencing −50%–70% tumor cells.
- Standardization of molecular assays:
  - Kit-based antibodies preferred for immunohistochemistry, with a simple standard scoring system needed.
  - FISH: Two-color FISH with CEP control, using the Colorado scoring system.\(^{90}\)
  - Mutational analysis: Direct sequencing; replicate PCR and sequencing reactions to establish mutation status of each sample amplicon.

The tumor biology of NSCLC prevents easy answers. Unlike CML that relies almost exclusively on the tyrosine kinase activated by the fusion Bcr-Abl,\(^{91}\) or a closer analogy, the overexpression of HER-2 in 25%–30% of breast cancers,\(^{92}\) carcinogenesis of NSCLC is not so heavily dependant on *EGFR* status (by any measure of *EGFR*). The absence of this "oncogene addiction"\(^{93}\) in NSCLC illustrates why patients with NSCLC will continue to require multimodal therapy for the foreseeable future.

**Future directions**

It is likely that the lessons on how to use cetuximab wisely may come from experience in patients with colon cancer. RAS is one of the downstream signaling molecules stimulated by active *EGFR*. Mutations that cause constitutive activation of the K-RAS oncogene predict resistance to cetuximab in colorectal cancer (CRC) cell lines.\(^{94}\) This study emerged in the wake of retrospective observations that patients who failed to respond to cetuximab were more likely to have mutated, constitutively activated K-RAS,\(^{95,96}\) although some studies observe good clinical response in patients with mutated K-RAS.\(^{97}\) A recently published study noted a mutation in the extracellular domain (R521K of exon 13) of *EGFR* that predicted response to cetuximab.\(^{97}\)

However these observations must be made with the caveat in mind that tumor biology of colon cancer is different from NSCLC. Somatic mutations in *EGFR* are almost never seen in CRC cell lines.\(^{98}\) Also cetuximab activity in colorectal cancer does not correlate with *EGFR* protein levels as measured by IHC\(^{54,99}\) but does correlate with gene copy number measured by FISH.\(^{100}\) Despite this, multiple trials in NSCLC have shown that mutant K-RAS predicts resistance to erlotinib.\(^{101,102}\)

Future investigations should stratify patients with respect to *EGFR* status and other potential predictive factors like K-RAS mutations. Future studies should address the predictive markers for cetuximab activity, be it gene amplification by FISH or protein overexpression by IHC or mutation analysis.
Also studies should be conducted to determine if cetuximab is useful in patients who have already failed an EGFR-TKI.

Disclosure
The authors report no conflicts of interest in this work.

References


